1 / 23

Osteoporosis Treatment

Osteoporosis Treatment. Dr. SAEED AHMED. osteoporosis. Bone undergoes a continuous remodeling, process involving bone resorption and formation. Any process that disrupt this balance by increasing resorption relative to formation results in osteoporosis. Drugs used in osteoporosis. Calcium

francisg
Télécharger la présentation

Osteoporosis Treatment

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Osteoporosis Treatment Dr. SAEED AHMED

  2. osteoporosis • Bone undergoes a continuous remodeling, process involving bone resorption and formation. • Any process that disrupt this balance by increasing resorption relative to formation results in osteoporosis Mahmoud Khattab

  3. Drugs used in osteoporosis • Calcium • Vit D • HRT(estrogen) • Raloxifene (SERM) • BISPHOPHONATES • Calcitonin • Teriparatide ( PTH, recombinant) Mahmoud Khattab

  4. Abnormal loss of bone & skeletal fragilitypredisposing to fractures. • In osteoporosis ! bone mineral density(BMD) is reduced & • bone microarchitecture is disrupted. Mahmoud Khattab

  5. Causes/ Risk factors: • Long-term use of glucocorticoides/ other drugs • As a manifestation of endocrine disease (thyrotoxicosis/ hyperparathyroidism) • Malabs syndrome • Alcohol abuse & cigarette smoking • Age > 65 yrs • Idiopathic. • Occur in elderly in both sexes, \ is most pronounced in postmenopausal women. Mahmoud Khattab

  6. Osteoporosis • In osteoporosis there is decreased bone mineral density (BMD) & disrupted bone architecture • This would increase fracture liability • Three hormones are responsible for Calcium homeostasis • Calcitonin • Parathyroid hormone • 1,25-OH-D3 production Mahmoud Khattab

  7. Calcitonin • Nature: A 32-amino acid-polypeptide secreted by parafollicular(C-) cells of the thyroid gland • Calcitonin acts to decrease calcium concentration via calcitonin receptors in osteoclasts, GIT, kidney & brain • Inhibits Ca2+ absorption by the intestines • Inhibits osteoclast activity in bones • Inhibits Ca2+/phosphate reabsorption by the kidney tubules • Post-menopausal women tend to possess lower levels of plasma calcitonin levels • Pharmaceutical formulations include: • Nasal spray • Parenteral formulation for IM or S.C. injection Mahmoud Khattab

  8. Calcitonin • Pharamcological Actions: • Osteoclasts size & motility are decreased leading to inhibition of bone resorption • It inhibits the parathyroid hormone-induced acceleration of bone turnover • GIT gastrin & pancreozymin or increased serum Ca2+ stimulate calcitonin secretion • It increases renal excretion of Na+, K+, Ca2+, Mg2+, and phosphate Mahmoud Khattab

  9. Calcitonin Pharmacokinetics • Rapid absorption from injection sites (slow with addition of gelatin) • Half-life is short of about 20 minutes • Weak protein binding • Renal and hepatic metabolism • Nasal spray calcitonin has 5-50% availability when compared to IM route Mahmoud Khattab

  10. Calcitonin adverse effects • Adverse effects are dose-dependent and more frequent with parenteral use but rarely observed after nasal spray administration • They include: • Anorexia, nausea, & fascial flushing • Urticaria or anaphylaxis is rare • Long-term use may lead to formation of antibodies that possibly are ineffective • Uncommon drug-drug interacions except for K+ depletion when calcitonin combined with thiazide diuretics Mahmoud Khattab

  11. Calcium and Vitamin D Vitamin D–Ca2+ absorption activation • PTH up-regulates 25-OH-vitaminD3-1-alpha-hydroxylase in the kidney • This enzyme activates hyroxylation of 25-OH-vitamin D, to its active form 1,25-dihydroxy vitamin D • This activated form of vitamin D increases the absorption of Ca2+ ions by the intestine via calbindin Mahmoud Khattab

  12. Calcium and Vitamin D Preparations • Ca chloride, Ca citrate, Ca lactate, Ca gluconate, and Ca carbonate (richest Ca source) • Insoluble Ca carbonate contains 40% elemental Ca2+, after conversion to Ca salts in the body • Vitamin D Used forms include: • Vitamin D2 (ergocalciferol) • Vitamin D3 (adequate amounts of vitamin D3 can be made in the skin after 10-15 min of sun exposure 2 times/week • 1,25-dihydroxyvitamin-D (calcitriol), the active form Mahmoud Khattab

  13. Calcium and Vitamin D • 1500 mg of Calcium and 800 IU of vitamin D per day are recommended for postmenopausal women • Vitamin D receptors (VDR) activation in the intestine, bone, kidney,& parathyroid gland cells leads to the maintenance of calcium and phosphorus levels in the blood & to the maintenance of bone content • Parathyroid hormone and calcitonin play a role Mahmoud Khattab

  14. Calcium and Vitamin DAdverse Effects • Oral calcium may cause • Gastric irritation, nausea & constipation • Excessive Ca→ hypercalcemic toxicity especially in presence of high vitamin D intake • Decreased tetracycline absorption • Vitamin D • Overdose → hypercalcemia & hyperphosphatemia • Renal dysfunction (nephro-lithisis & -calcinosis) • Localised/generalised lowered bone density • GIT complaints Mahmoud Khattab

  15. Hormone Replacement Therapy (HRT) • Estrogen deficiency causes bone loss via increased bone resorption over bone formation • Loss of estrogen→ ↑IL-1, IL-6 & TNF-α → enhance osteoclast replication & differentiation • HRT Beneficial Effects: • HRT increases BMD → beneficial in vertebral & non-vertebral fractures • Control of menopausal/urogenital symptoms • Reduced risk of colon cancer • HRT Risk: ↑CV & CerebroV diseases, gall bladder disease, DVT, pulmonary emboli, & breast cancer Mahmoud Khattab

  16. Selective Estrogen Receptor Modulators (SERMs)Raloxifene • Non-hormonal agents that bind to estrogen receptors with an affinity equivalent to estradiol • They induce estrogen-like effects in some but not all tissues • Raloxifene (60 mg/day) is the only approved member for prevention & treatment of osteoporosis • Pharmacokinetics: • It is rapidly absorbed by 60% from oral route • It has low bioavailability (2%) because of extensive first-pass metabolism and glucuronide conjugation • It has high plasma protein binding • Cholestyramine reduces absorption & enterohepatic cycling Mahmoud Khattab

  17. RaloxifeneEffects on BMD and Bone Turnover • Clinical evidence (MORE) of 30-50% reduction of vertebral fractures • Non-vertebral fractures are either non-significantly affected or reduced in women with severe vertebral factures • Significant increase of BMD in the lumbar spine and femoral neck • Reduction of bone turnover markers Mahmoud Khattab

  18. RaloxifeneExtra-Skeletal and Adverse Effects • Reduction of total lipids and LDL-cholesterol • Reduction of CVD risk ONLY in women at high risk or with established CVD • Reduction of incidence of the estrogen receptor-dependent invasive breast cancer in low-risk osteoporotic post-menopausal women • Adverse Effects It is safe and well-tolerated • Increased hot flashes & leg cramps • Infrequent venous thromboembolism (VTE), not related to leg cramps • Contraindicated in patients with VTE history Mahmoud Khattab

  19. Bisphosphonates • They are used for many bone diseases including: osteoporosis, Paget’s disease, malignacy hypercalcemia and bone metastases • They have a very high affinity for bone tissue, • 50% of administered dose is excreted unchanged by the kidney, the remainder is rapidly taken up by the osteoclasts • Pharmacokinetics: • Poor absorption (2% during fasting) • Food reduces absorption • T1/2: 1 hour • Administered 1 hour before meals with water only Mahmoud Khattab

  20. Pyrophosphate-like Etidronate Metabolised in the cell to forming a nonfunctional cytotoxic ATP molecules Apoptosis/cell death of osteoclast occurs leading to a decrease in the breakdown of bone Nitrogen-containing Alendronate & Risedronate 1000-times more potent Blocking the enzyme farnesyl diphosphate synthase (FPPS) in the HMG-CoA reductase (the mevalonate) pathway This prevents the formation of two metabolites essential for connecting some small proteins to the cell membrane (prenylation) Proper sub-cellular protein trafficking is impaired as well BisphosphonatesMechanism of Action J Bone Miner Res. 1997, 12(9): 1358-67 Bone 2003; 33 (5): 805–11 Mahmoud Khattab

  21. BisphosphonatesAdverse Effects • Oral N-containing bisphosphonates may cause upset stomach and inflammation & erosions of the esophagus, can be prevented by remaining seated upright for 30 to 60 minutes after taking the medication • N-containing bisphosphonates contraindicted with esophageal pathology • Intravenous bisphosphonates can give fever and flu-like symptoms after the first infusion only • A slightly increased risk for electrolyte disturbances • In chronic renal failure, the drugs are excreted much more slowly, and dose adjustment is required • At high doses, etidronate may cause osteomalcia Mahmoud Khattab

  22. Parathyroid Hormone (PTH)Teriparatide {rhPTH(1-34)} • Recombinant hPTH(1-34) showed good efficacy against vertebral & non-vertebral fractures in post-menopausal women • It increases BMD at skeleton sites except radius • It increases BMD at the spine in severe osteoporotic men & glucocorticoid-induced osteoporosis postmenopausal women • Adverse effects: • Nausea, headache, dizziness • Infrequently leg cramps • Occasional hypercalcemia &/or hypercalciuria Mahmoud Khattab

  23. Parathyroid Hormone (PTH)Reminder of Activity • PTH acts to increase the concentration of calcium in the blood by acting upon PTHR in three organs • Bone: It enhances the release of calcium from the large reservoir contained in the bones • Kidney: It enhances active re-absorption of calcium and magnesium from distal tubules and the thick ascending limb and increases the excretion of phosphate • Intestine: It enhances the absorption of calcium in the intestine by increasing the production of activated vitamin D in the kidney Mahmoud Khattab

More Related